News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer
Raffaele Colombo/LinkedIn
Oct 4, 2024, 17:28

Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Raffaele Colombo shared a post on X:

“sBLA for trastuzumab deruxtecan (T-DXd) has been accepted by FDA (and granted Priority Review) for patients with HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining < IHC 1+) breast cancer after at least one endocrine therapy, based on DESTINY-Breast06.”

Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Source: Raffaele Colombo/X

Raffaele Colombo, a  leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.

Breast Cancer cancer cancer awareness cancer care DESTINY-Breast06 FDA fight against cancer Global fight against cancer HER2 OncoDaily Oncology Raffaele Colombo
Special Coverage
Career
Dec 21, 2024, 07:45
OncoInfluencers to Follow on Social Media: Dr. Liang Cheng
Insight
Dec 21, 2024, 07:31
Update on U.S. regulatory review of subcutaneous amivantamab for EGFR + lung cancer
Science
Dec 21, 2024, 07:05
Naseema Gangat: Practical prognostic tool for the current standard of care in older/unfit AML
Blog
Dec 21, 2024, 05:54
LCC in Spanish: LALCA 2024 Highlights
Blog
Dec 21, 2024, 05:50
The Opportunities Are Endless: CU Cancer Center leader Enrique Soto Pérez de Celis signs key international agreement
Insight
Dec 21, 2024, 05:42
Raffaella Casolino: How to integrate cancer into crisis?
Insight
Dec 21, 2024, 05:01
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Blog
Dec 21, 2024, 05:01
Omolola Salako: A year ago, Pearl Oncology Specialist Hospital became a 24-hour, 10-bed cancer center
Science
Dec 21, 2024, 04:57
Alexandre Chan: Updates on repurposing riluzole as a treatment for cancer-related cognitive impairment
Blog
Dec 21, 2024, 04:55
Milan Mishkovikj: The Patient at the Center - Value-Based Healthcare in Oncology
Insight
Dec 21, 2024, 04:52
Do national cancer control plans address care and research for children and AYAs - SIOP
Insight
Dec 21, 2024, 04:36
A holistic global strategy for incorporating cancer care into crisis response initiatives - The Institute of Cancer and Crisis